Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment

Hiroshi Takei, Satoshi Takanashi, Kotaro Otomo, Hironari Hanaoka, Jun Kikuchi, Kunihiro Yamaoka, Keiko Yoshimoto, Takayuki Abe, Tsutomu Takeuchi, Yuko Kaneko

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Objectives: To investigate the efficacy and safety of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA). Methods: Patients with active RA, despite conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), were recruited. HCQ was administered for 24 weeks, in addition to prior treatment. The primary end-point was the proportion of patients achieving American College of Rheumatology (ACR) 20 at Week 24, compared to that of a propensity score–matched historical control group. Results: Sixty patients were enrolled and administered HCQ. We also identified 276 patients as candidates for the historical control group. Propensity score matching yielded 46 patients in each group. The proportion of patients achieving ACR20 at Week 24 was significantly higher in the HCQ group than in the control group (54.4% vs. 28.3%, P = .007). The proportion of patients achieving ACR50 and ACR70 at Week 24 were also higher in the HCQ group than in the control group (ACR50, 30.4% vs. 4.3%, P = .006; ACR70, 17.4% vs. 0%, P = .005). Neither HCQ retinopathy nor any new safety signal was observed during the study. Conclusion: The addition of HCQ to csDMARDs was effective, with no new safety signal in patients with RA.

本文言語English
ページ(範囲)50-59
ページ数10
ジャーナルModern rheumatology
34
1
DOI
出版ステータスPublished - 2024 1月 1

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル